SecBot SecBot
8-K ·Filed Nov 2, 2026

BVS

Bioventus Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed14d 11h ago SEC0001665988-26-000050
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The revenue miss and lowered top-end guidance are modest negatives, but the ongoing strategic alternatives review (including a potential sale) provides a counterbalancing catalyst. Watch for any announcement regarding the strategic review outcome, which could include a sale of the company.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Bioventus reported Q3 2026 revenue of $142.4M (+3% YoY), slightly below the $149.5M consensus, and non-GAAP EPS of $0.17, in line with the $0.17 consensus. The company narrowed its full-year net sales guidance to $590M-$595M (from $600M-$610M), reflecting ~4-5% growth, while reaffirming adjusted EPS of $0.75-$0.79. The ongoing strategic alternatives review, initiated after an unsolicited acquisition proposal in Q2, continues with no set timetable.

Key Financial Metrics

EPS (Adj.)
$0.17
est $0.17 · 0.0% · GAAP: $0.08
Revenue
$142.4M
est $149.5M · -4.7% · +2.7% YoY
Rating
in line
Guidance
$590M-$595M
lowered
Gross Margin
68.2%

Key Facts

  • Q3 2026 revenue of $142.4M, up 3% YoY from $138.7M
  • GAAP diluted EPS of $0.08 vs $0.05 in prior year
  • Non-GAAP EPS of $0.17 vs $0.15 in prior year, in line with $0.17 consensus
  • Revenue of $142.4M missed consensus of $149.5M
  • Full-year net sales guidance narrowed to $590M-$595M from $600M-$610M
  • Adjusted EPS guidance reaffirmed at $0.75-$0.79
  • Adjusted EBITDA of $28.4M, up 7% YoY from $26.6M
  • Cash from operations of $20.7M in Q3
  • Company continues to review strategic alternatives after receiving unsolicited acquisition proposal in Q2
  • Made $15M discretionary principal prepayment on term loan in Q3

Financial Impact

Revenue miss of ~$7.1M vs consensus; guidance narrowed lower by $10M-$15M at the top end

revenueepsguidance

Segment Breakdown

SegmentRevenueGrowth
Pain Treatments$71.3M+6.2%
Surgical Solutions$50.5M+0.7%
Restorative Therapies$20.6M-3.4%

Risk Factors

  • Revenue growth slowing to 3% in Q3 vs 4% in Q2 and 6-7% full-year guidance initially
  • Restorative Therapies segment declining 3.4% YoY, driven by EXOGEN weakness
  • No timetable for strategic alternatives review; process could be protracted or yield no transaction
  • Cash and cash equivalents declined to $30.7M from $51.2M at year-end 2025

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001665988-26-000050
Document: bvs-20261102.htm0001665988-26-000050
Document: 0001665988-26-000050-index-headers.html0001665988-26-000050
Document: 0001665988-26-000050-index.html0001665988-26-000050
Document: 0001665988-26-000050.txt0001665988-26-000050
8-K Data (Synthetic)0001665988-26-000050

Track record

18 reports on BVS

Performance horizon

2 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +37.19% at T+60 after the May 8, 2026 report. 3 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $10.66 Now $10.46 −1.88% settles Feb 11
  2. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $10.61 Now $10.46 −1.41% settles Feb 4
  3. Nov 2, 202614d ago 8-K Neutral 5/10 Viewing No price data
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $10.95 Now $10.46 −4.43% settles Feb 1
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $14.65 Now $10.46 −28.60% settles Jan 26
  6. Aug 15, 202613w ago Institutional Cluster Mixed 5/10 Entry $13.88 to $11.02 Now $10.46 −24.64% ▼ −20.64% −17.88% vs SPY
  7. Aug 5, 202614w ago 8-K Bullish 7/10 No price data
  8. Aug 5, 202614w ago Press Release Bullish 7/10 Entry $15.26 to $14.86 Now $10.46 −31.45% ▼ −2.62% −2.81% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $8.68 to $14.07 Now $10.46 −20.51% ▼ −62.10% −57.70% vs SPY
  10. Jun 2, 202623w ago Press Release Bearish 6/10 Entry $8.11 to $13.97 Now $10.46 −28.98% ▼ −72.26% −71.14% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026